CDKN2A and glioblastoma: One systematic review reported that glioblastoma patients had shorter PFS in the presence of CDKN2A homozygous deletion in two studies (median values, 16 vs. 30 months) and shorter OS in four studies (median values, 38 vs. 86 months) [11].